Notice of Designation of Scarce Materials or Threatened Materials Subject to COVID-19 Hoarding Prevention Measures; Change in Information Contact, Removal of Chloroquine Phosphate and Hydroxychloroquine HCl; Correction, 40667-40668 [2020-14525]

Download as PDF 40667 Federal Register / Vol. 85, No. 130 / Tuesday, July 7, 2020 / Notices Institute Evidence-Based Management of SCD Expert Panel Report; (2) using tele-mentoring, telemedicine and other provider support strategies to increase the number of providers administering evidence-based sickle cell care; and (3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home. Per the statutory requirement, the data collected will be used to evaluate the program and will be published in a report to Congress. A 60-day notice published in the Federal Register on January 23, 2020, vol. 85, No. 15; pp. 3935–37. There were no public comments. Need and Proposed Use of the Information: The purpose of the proposed QI and PM data collection is to evaluate the effectiveness of the SCDTDRCP and how the program can improve the coordination of service delivery for individuals with sickle cell disease, train health professionals to increase access to quality care and collaborate with various stakeholders to optimize health outcomes for individuals with sickle cell disease. Pursuant to 42 U.S.C. 300b–5(b)(3)(B), the National Coordinating Center (NCC) will work with the grantees to gather data and prepare a Report to Congress at the conclusion of the program. Quality Improvement All five SCDTDRCP grantees are required to conduct QI initiatives to improve quality of SCD treatment and access to care. Each grantee also works with and supports local sites (i.e., university, medical center, etc.) that provide SCD care within their region to implement QI initiatives. All the grantees and local sites are required to implement initiatives to increase the hydroxyurea use and conduct one or more additional QI initiatives on the following topics: pneumococcal vaccinations, Transcranial Doppler screening, and transition planning. The grantees and local sites will collect data on a quarterly basis on applicable measures depending on which QI initiatives they are undertaking. The data will be extracted from patients’ charts either via chart reviews or electronic health records. The local sites will send their data to the grantees using an excel spreadsheet or by entering data into a database form of their choice developed by the grantee. The grantees will aggregate their own data and the data received from the local sites and submit the aggregate data to the NCC. Performance Measures In order to understand SCD care provided and the reach of the SCDTDRCP activities across regions, seven PM have been established (e.g. number of SCD patients seen by a provider in the past year). The five SCDTDRCP grantees will send a survey once a year to providers they work with within their region who provide care to SCD patients to collect PM data. Once the providers complete the survey, the grantees will aggregate the individual responses and submit the PM data to the NCC. Likely Respondents: For QI data, the five SCDTDRCP grantees and local sites that provide SCD care that the grantees work with. For PM data, the five SCDTDRCP grantees and providers the grantees work with within their region who provide care to SCD patients. Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the tables below: TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Number of respondents Form name Number of responses per respondent per year Total responses per year Average burden per response (hrs/yr) Total burden hours per year SCDTDRCP ......................................................................... Quality Improvement Measures* ......................................... SCDTDRCP Performance Measures .................................. 55 305 4 1 220 305 13 1 2,860 305 Total .............................................................................. 360 ........................ 525 ........................ 3,165 * Note: Total burden hours per year shown represents the maximum number of estimated hours. Actual hours may be lower since many of the respondents may not be collecting data all QI initiatives. Maria G. Button, Director, Executive Secretariat. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2020–14612 Filed 7–6–20; 8:45 am] jbell on DSKJLSW7X2PROD with NOTICES BILLING CODE 4165–15–P Office of the Secretary Notice of Designation of Scarce Materials or Threatened Materials Subject to COVID–19 Hoarding Prevention Measures; Change in Information Contact, Removal of Chloroquine Phosphate and Hydroxychloroquine HCl; Correction Office of the Secretary (OS), DHHS. ACTION: Notice; correction. AGENCY: VerDate Sep<11>2014 16:59 Jul 06, 2020 Jkt 250001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 This document updates the March 30, 2020, Federal Register Notice entitled ‘‘Notice of Designation of Scarce Materials or Threatened Materials Subject to COVID–19 Hoarding Prevention Measures,’’ by replacing the named contact and updating the ‘‘Notice of Designation of Scarce Materials or Threatened Materials’’ section. SUMMARY: FOR FURTHER INFORMATION CONTACT: Paige Ezernack, Office of the Assistant Secretary for Preparedness and Response, Office of Strategy, Policy, Planning, and Requirements, Suite E:\FR\FM\07JYN1.SGM 07JYN1 40668 Federal Register / Vol. 85, No. 130 / Tuesday, July 7, 2020 / Notices 5440—O’Neill House Office Building, 200 C Street SW, Washington, DC 20201, (202) 260–0365. SUPPLEMENTARY INFORMATION: I. Background In FR Doc. 2020–06641 of March 30, 2020 (85 FR 17592–17593), the contact for more information is now aspr.dpa@ hhs.gov. Chloroquine phosphate and hydroxychloroquine HCl are no longer listed as scarce or threatened materials following the withdrawal of the FDA emergency use authorizations for these drugs on June 15, 2020. II. Correction of Errors In FR Doc. 2020–06641 of March 30, 2020 (85 FR 17592–17593), make the following corrections: On page 17592, first full column, in FR Doc. 2020–06641, Further Information section, change Bryan Shuy: 202–703–8610; bryan.shuy@ hhs.gov (mail to: Bryan.Shuy@hhs.gov) to the ASPR DPA Office: 202–838–3420; aspr.dpa@hhs.gov. On page 17593, first column, in FR Doc. 2020–06641, Notice of Designation of Scarce Materials or Threatened Materials, remove ‘‘Drug product with active ingredient chloroquine phosphate or hydroxychloroquine HCl.’’ Dated: June 30, 2020. Wilma Robinson, Deputy Executive Secretary, Department of Health and Human Services. [FR Doc. 2020–14525 Filed 7–6–20; 8:45 am] BILLING CODE 4150–37–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jbell on DSKJLSW7X2PROD with NOTICES National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; VerDate Sep<11>2014 16:59 Jul 06, 2020 Jkt 250001 Training Programs for Institutions that Promote Diversity (T32). Date: August 5, 2020. Time: 11:00 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20814 (Telephone Conference Call). Contact Person: Zhihong Shan, Ph.D., MD, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 205–J, Bethesda, MD 20892, 301–827–7985, zhihong.shan@nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Catalyze: Enabling Technologies. Date: August 6, 2020. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20814 (Telephone Conference Call). Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209–B, Bethesda, MD 20892, (301) 435–0297, goltrykl@mail.nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Stimulating Access to Research in Residency (StARR). Date: August 21, 2020. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Kristen Page, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209–B, Bethesda, MD 20892, (301) 827–7953, kristen.page@nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Bench to Bassinet Coordinating Center. Date: August 21, 2020. Time: 3:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Tony L. Creazzo, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 207–Q, Bethesda, MD 20892–7924, (301) 827–7913, creazzotl@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) PO 00000 Frm 00049 Fmt 4703 Sfmt 9990 Dated: June 30, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–14478 Filed 7–6–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Tools to Address COVID–19 Pandemic. Date: July 27, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute, 9609 Medical Center Drive, Room 7W608, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W608, Rockville, MD 20850, 240–276–5856, nadeem.khan@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: June 30, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–14480 Filed 7–6–20; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\07JYN1.SGM 07JYN1

Agencies

[Federal Register Volume 85, Number 130 (Tuesday, July 7, 2020)]
[Notices]
[Pages 40667-40668]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14525]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Notice of Designation of Scarce Materials or Threatened Materials 
Subject to COVID-19 Hoarding Prevention Measures; Change in Information 
Contact, Removal of Chloroquine Phosphate and Hydroxychloroquine HCl; 
Correction

AGENCY: Office of the Secretary (OS), DHHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: This document updates the March 30, 2020, Federal Register 
Notice entitled ``Notice of Designation of Scarce Materials or 
Threatened Materials Subject to COVID-19 Hoarding Prevention 
Measures,'' by replacing the named contact and updating the ``Notice of 
Designation of Scarce Materials or Threatened Materials'' section.

FOR FURTHER INFORMATION CONTACT: Paige Ezernack, Office of the 
Assistant Secretary for Preparedness and Response, Office of Strategy, 
Policy, Planning, and Requirements, Suite

[[Page 40668]]

5440--O'Neill House Office Building, 200 C Street SW, Washington, DC 
20201, (202) 260-0365.

SUPPLEMENTARY INFORMATION:

I. Background

    In FR Doc. 2020-06641 of March 30, 2020 (85 FR 17592-17593), the 
contact for more information is now [email protected]. Chloroquine 
phosphate and hydroxychloroquine HCl are no longer listed as scarce or 
threatened materials following the withdrawal of the FDA emergency use 
authorizations for these drugs on June 15, 2020.

II. Correction of Errors

    In FR Doc. 2020-06641 of March 30, 2020 (85 FR 17592-17593), make 
the following corrections:
    On page 17592, first full column, in FR Doc. 2020-06641, Further 
Information section, change Bryan Shuy: 202-703-8610; 
[email protected] (mail to: [email protected]) to the ASPR DPA 
Office: 202-838-3420; [email protected].
    On page 17593, first column, in FR Doc. 2020-06641, Notice of 
Designation of Scarce Materials or Threatened Materials, remove ``Drug 
product with active ingredient chloroquine phosphate or 
hydroxychloroquine HCl.''

    Dated: June 30, 2020.
Wilma Robinson,
Deputy Executive Secretary, Department of Health and Human Services.
[FR Doc. 2020-14525 Filed 7-6-20; 8:45 am]
BILLING CODE 4150-37-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.